Action 1541 IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Actions

1541

CNE100006624

Temps Différé Hong Kong S.E.
Autres places de cotation
 04:16:59 18/07/2024 		Varia. 5j. Varia. 1 janv.
12,94 HKD +0,62 % Graphique intraday de ImmuneOnco Biopharmaceuticals (Shanghai) Inc. -0,31 % -56,72 %
03/07 ImmuneOnco administre le premier patient dans le cadre de l'essai clinique de phase 3 d'un médicament contre le lymphome hodgkinien MT
03/07 ImmuneOnco Biopharmaceuticals (Shanghai) Inc. annonce des mises à jour sur l'essai clinique de l'IMM01 (Timdarpacept) en combinaison avec le Tislelizumab CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
ImmuneOnco Doses First Patient in Phase 3 Clinical Trial of Hodgkin Lymphoma Drug
ImmuneOnco Biopharmaceuticals Inc. Announces Updates on the Clinical Trial of IMM01 (Timdarpacept) in Combination with Tislelizumab
ImmuneOnco Biopharmaceuticals Gets IND Approval for NMOSDs Drug Trial in China
ImmuneOnco Biopharmaceuticals Inc. Obtains Investigational New Drug Approval for the Phase Ib/III Clinical Trial of IMC-002
ImmuneOnco Biopharmaceuticals Gets China's Phase 3 Trial Approval for Leukemia Drug
ImmuneOnco Completes Filing with China Regulator for Conversion of H Shares
ImmuneOnco Biopharmaceuticals Inc. Approves the Appointment of Guan Mei as Executive Director
Immuneonco Biopharmaceuticals Gets Regulatory Go-Ahead for Phase 3 Trial of Myelodysplastic Syndrome Drug in China
Immuneonco Biopharmaceuticals Inc. Receives Approval from the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China for A Randomized, Double-Blind, Controlled Phase III Clinical Trial of MM01 (Timdarpacept) in Combination with Azacitidine for the First-Line Treatment of Higher-Risk Myelodysplastic Syndrome (HR MDS)
ImmuneOnco Obtains Chinese Nod for Phase III Trials of Anti-Cancer Medication
ImmuneOnco Biopharmaceuticals Inc. Receives Approval from the National Medical Products Administration of the People's Republic of China for the Protocol of the Phase Iii Clinical Trial of IMM01
Immuneonco Biopharmaceuticals' 2023 Loss Narrows as Other Income Increases
ImmuneOnco Biopharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Immuneonco Biopharmaceuticals CFO Resigns
Immuneonco Biopharmaceuticals Inc. Announces Board and Executive Changes
ImmuneOnco Begins Phase II Clinical Trial of Anti-Tumor Drug
ImmuneOnco Biopharmaceuticals Inc. Announces First Patient Dosed in the Phase II Clinical Trial of IMM2510 for the Treatment of Refractory or Relapsed Alveolar Soft Part Sarcoma
ImmuneOnco Biopharmaceuticals Gets US FDA's Orphan-Drug Designation for Leukemia Drug Combination
ImmuneOnco Biopharmaceuticals Gets Nod to Trial Cancer Drug
ImmuneOnco Biopharmaceuticals Inc. Receives an Investigational New Drug Approval from the National Medical Products Administration of the People's Republic of China
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 1541
  4. Actualités ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
  5. Autres langues